RATIONALE: Delta9-Tetrahydrocannabinol (THC) is the main active constituent of cannabis. In recent years, the average THC content of some cannabis cigarettes has increased up to approximately 60 mg per cigarette (20% THC cigarettes). The pharmacokinetics of THC after smoking cannabis cigarettes containing more than approximately 35 mg THC (3.55% THC cigarettes) is unknown. To be able to perform suitable exposure risk analysis, it is important to know if there is a linear relation at higher doses. OBJECTIVES: The present study aimed to characterise the pharmacokinetics of THC, the active metabolite 11-OH-THC and the inactive metabolite THC-COOH after smoking a combination of tobacco and cannabis containing high THC doses. MATERIALS AND METHODS: This double-blind, placebo-controlled, four-way, cross-over study included 24 male non-daily cannabis users (two to nine joints per month). Participants were randomly assigned to smoke cannabis cigarettes containing 29.3, 49.1 and 69.4 mg THC and a placebo. Serial serum samples collected over a period of 0-8 h were analysed by liquid chromatography electrospray tandem mass spectrometry. Effects on heart rate, blood pressure and 'high' feeling were also measured. RESULTS:Mean maximal concentrations (Cmax) were 135.1, 202.9 and 231.0 microg/L for THC and 9.2, 16.4 and 15.8 microg/L for 11-OH-THC after smoking a 29.3-, 49.1- and 69.4-mg THC cigarette, respectively. A large inter-individual variability in Cmax was observed. Heart rate and 'high' feeling significantly increased with increasing THC dose. CONCLUSIONS: This study demonstrates that the known linear association between THC dose and THC serum concentration also applies for high THC doses.
RCT Entities:
RATIONALE: Delta9-Tetrahydrocannabinol (THC) is the main active constituent of cannabis. In recent years, the average THC content of some cannabis cigarettes has increased up to approximately 60 mg per cigarette (20% THC cigarettes). The pharmacokinetics of THC after smoking cannabis cigarettes containing more than approximately 35 mg THC (3.55% THC cigarettes) is unknown. To be able to perform suitable exposure risk analysis, it is important to know if there is a linear relation at higher doses. OBJECTIVES: The present study aimed to characterise the pharmacokinetics of THC, the active metabolite 11-OH-THC and the inactive metabolite THC-COOH after smoking a combination of tobacco and cannabis containing high THC doses. MATERIALS AND METHODS: This double-blind, placebo-controlled, four-way, cross-over study included 24 male non-daily cannabis users (two to nine joints per month). Participants were randomly assigned to smoke cannabis cigarettes containing 29.3, 49.1 and 69.4 mg THC and a placebo. Serial serum samples collected over a period of 0-8 h were analysed by liquid chromatography electrospray tandem mass spectrometry. Effects on heart rate, blood pressure and 'high' feeling were also measured. RESULTS: Mean maximal concentrations (Cmax) were 135.1, 202.9 and 231.0 microg/L for THC and 9.2, 16.4 and 15.8 microg/L for 11-OH-THC after smoking a 29.3-, 49.1- and 69.4-mg THC cigarette, respectively. A large inter-individual variability in Cmax was observed. Heart rate and 'high' feeling significantly increased with increasing THC dose. CONCLUSIONS: This study demonstrates that the known linear association between THC dose and THC serum concentration also applies for high THC doses.
Authors: Scott D Lane; Don R Cherek; Oleg V Tcheremissine; Lori M Lieving; Cythia J Pietras Journal: Neuropsychopharmacology Date: 2005-04 Impact factor: 7.853
Authors: Naveen K Neradugomma; Kaitlyn Drafton; Diana R O'Day; Michael Z Liao; Lyrialle W Han; Ian A Glass; Qingcheng Mao Journal: Placenta Date: 2018-05-09 Impact factor: 3.481
Authors: Ryan Vandrey; Evan S Herrmann; John M Mitchell; George E Bigelow; Ronald Flegel; Charles LoDico; Edward J Cone Journal: J Anal Toxicol Date: 2017-03-01 Impact factor: 3.367
Authors: Claudine C Hunault; Tjeert T Mensinga; Koen B E Böcker; C Maarten A Schipper; Maaike Kruidenier; Marianne E C Leenders; Irma de Vries; Jan Meulenbelt Journal: Psychopharmacology (Berl) Date: 2008-12-20 Impact factor: 4.530
Authors: Claudine C Hunault; Koen B E Böcker; R K Stellato; J Leon Kenemans; Irma de Vries; Jan Meulenbelt Journal: Psychopharmacology (Berl) Date: 2014-05-31 Impact factor: 4.530
Authors: Marcoita T Gilbert; Kathleen K Sulik; Eric W Fish; Lorinda K Baker; Deborah B Dehart; Scott E Parnell Journal: Neurotoxicol Teratol Date: 2015-12-18 Impact factor: 3.763